We bring you the latest updates from The Strategy Story through a simple and fast subscription.
We can deliver your news in your inbox, on your phone or you can read them here on this website on your personal news page.
Unsubscribe at any time without hassle.
The Strategy Story's title: The Strategy Story - Simplifying Business Strategies
Is this your feed? Claim it!
Unilever makes money by selling branded consumer goods in very large volumes across more than 190 countries. These include shampoo, deodorant, skin care, laundry detergent, surface cleaners, bouillon, mayonnaise and vitamins. Revenue comes from wholesale sales to retailers, distributors and e-commerce platforms,...
AstraZeneca PLC is a UK-headquartered, science-led pharmaceutical company. This analysis uses the company’s 2025 annual report and results for the six months ended 30 June 2026. Figures are reported in USD, its reporting currency. Management ambitions and guidance are distinguished from realised results.
1. Scale oncology leadershipAstraZeneca’s largest therapy area g...
AstraZeneca PLC is a UK-headquartered, science-led pharmaceutical company. This analysis uses the company’s 2025 annual report and results for the six months ended 30 June 2026. Figures are reported in USD, its reporting currency. Management ambitions and guidance are distinguished from realised results.
Drug discovery and intellectual propertyAstraZeneca develops med...
AstraZeneca SWOT Analysis in 2026, based on its 2025 annual disclosures and July 2026 interim results.
StrengthsOncology contributed USD 14.124 billion of first-half 2026 revenue, representing 46 percent of group revenue. Rare Disease contributed USD 4.911 billion. The pipeline contained 183 projects, including 21 late-stage new molecular entities. The global commerci...
AstraZeneca PESTEL Analysis in 2026 assesses external influences on its research, manufacturing and global commercial operations. It draws on the company’s 2025 annual report and July 2026 interim results.
Political Pricing and procurementGovernment procurement can change realised medicine prices. China volume-based procurement affected first-half 2026 performance eve...